SCHEMBL23294448

SCHEMBL23294448

Cc1ncnc2c1ncn2[C@@H]1O[C@H]([C@](C)(O)c2ccc(Cl)c(Cl)c2)[C@@H](O)[C@H]1O

nearest known ligand 0.82

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 18/20 0.82
▸ WDR77 Q9BQA1 17/20 0.82
▸ SLC29A1 Q99808 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29705921 1.00 PRMT5 (0.82) PRMT5WDR77SLC29A1
SCHEMBL22508962 1.00 PRMT5 (0.82) PRMT5WDR77SLC29A1
SCHEMBL29706082 0.90 PRMT5 (1.00) PRMT5WDR77
SCHEMBL22501903 0.90 PRMT5 (1.00) PRMT5WDR77
SCHEMBL22501904 0.90 PRMT5 (1.00) PRMT5WDR77
SCHEMBL24146563 0.86 PRMT5 (0.73) PRMT5WDR77
SCHEMBL24146564 0.86 PRMT5 (0.73) PRMT5WDR77
SCHEMBL30128302 0.86 PRMT5 (0.73) PRMT5WDR77
SCHEMBL22501965 0.86 PRMT5 (1.00) PRMT5WDR77
SCHEMBL22501964 0.86 PRMT5 (1.00) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220218732-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED 2022-07-14 — — US disclosed
US-20220218732-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED 2022-07-14 — — US disclosed
US-11220524-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2022-01-11 — — US disclosed
US-11220524-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRELUDE THERAPEUTICS INCORPORATED (US) 2022-01-11 — — US disclosed
US-20210130388-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED 2021-05-06 — — US disclosed
US-20210130388-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED 2021-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130388-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 59/4885SLC29A1 3941/4885
US-20220218732-A1 Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 52/4885SLC29A1 3627/4885
US-11220524-B2 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 59/4885SLC29A1 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback